If you are wondering whether Organon’s current share price reflects its true worth, this article will walk through what the numbers actually say about the stock’s value. Organon last closed at US$7.29 ...

Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

The average one-year price target for Organon (NYSE:OGN) has been revised to $9.86 / share. This is a decrease of 10.77% from the prior estimate of $11.05 dated November 7, 2025. The price target is ...

Small-cap outperformance has narrowed over the last couple of weeks as investor caution increased, with volatility and geopolitical risk weighing on risk appetite and narrowing the performance gap vs.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars ...

Organon (NYSE:OGN) is gearing up to announce its quarterly earnings on Monday, 2025-11-10. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Organon (OGN) stock slides on weak earnings and pressure in Women’s Health; see Quant ratings, analyst views, and oversold upside potential—read now.

In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months.